<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880876</url>
  </required_header>
  <id_info>
    <org_study_id>3030-302-002</org_study_id>
    <nct_id>NCT04880876</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)</brief_title>
  <official_title>A Phase 3, Long-term Safety Study of Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the long-term safety of oral Eluxadoline administered to pediatric&#xD;
      participants with IBS-D who have completed study intervention in the Phase 2 study&#xD;
      3030-202-002 or the Phase 3 study 3030-303-002.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">April 28, 2028</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Clinically Significant Laboratory Values (clinical chemistry, complete blood count, urinalysis) as assessed by the Investigator</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Clinically Significant ECGs as assessed by the Investigator</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Clinically Significant vital sign measurements as assessed by the Investigator</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with any new Physical examination abnormality or worsening of change from baseline</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with any new neurological abnormality post baseline or worsening of change from baseline</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Open Label 6-11 years of age: Eluxadoline 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eluxadoline two 25mg tablets, oral administration, twice daily with food. Take at approximately the same time each day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label 12-17 years of age: Eluxadoline 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eluxadoline one 100mg tablet, oral administration, twice daily with food. May use 25mg tablets to administer 100mg dose. Take at approximately the same time each day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Blind 6-11 years of age: Eluxadoline 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Blind 6-11 years of age: Eluxadoline 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Blind 12-17 years of age: Eluxadoline 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Blind 12-17 years of age: Eluxadoline 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Blind 12-17 years of age: Eluxadoline 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinding will be accomplished via administration of a constant number of oral tablets in each age group (6 to 11 years of age and 12 to 17 years of age) where all participants in an age group will receive the same total number of oral tablets at each administration. Phase 2 completers who choose to remain on double-blind eluxadoline and received placebo in the lead-in Phase 2 study 3030-202-002 will be assigned to double-blind eluxadoline 25 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25mg Eluxadoline</intervention_name>
    <description>Oral Tablets</description>
    <arm_group_label>Double Blind 12-17 years of age: Eluxadoline 100mg</arm_group_label>
    <arm_group_label>Double Blind 12-17 years of age: Eluxadoline 25mg</arm_group_label>
    <arm_group_label>Double Blind 12-17 years of age: Eluxadoline 50mg</arm_group_label>
    <arm_group_label>Double Blind 6-11 years of age: Eluxadoline 25mg</arm_group_label>
    <arm_group_label>Double Blind 6-11 years of age: Eluxadoline 50mg</arm_group_label>
    <arm_group_label>Open Label 12-17 years of age: Eluxadoline 100 mg</arm_group_label>
    <arm_group_label>Open Label 6-11 years of age: Eluxadoline 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100mg Eluxadoline</intervention_name>
    <description>Oral Tablets</description>
    <arm_group_label>Open Label 12-17 years of age: Eluxadoline 100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants must be 6 to 17 years of age (inclusive)&#xD;
&#xD;
          -  Participants must have completed study intervention in their lead-in study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has an unresolved AE or a clinically significant finding on a physical&#xD;
             examination, vital sign assessment, or neurological assessment along with an ECG or&#xD;
             clinical laboratory tests (if results are available by the time of enrollment) that;&#xD;
             in the opinion of the investigator, could represent a safety concern or a condition&#xD;
             that would be exclusionary, could prevent the participant from performing any protocol&#xD;
             assessments, or could confound study assessments.&#xD;
&#xD;
          -  Participant has known allergies or hypersensitivity to opioids&#xD;
&#xD;
          -  Female participants who are currently pregnant or nursing, or plan to become pregnant&#xD;
             or nurse during the clinical study.&#xD;
&#xD;
          -  Participant has no gallbladder, (ie, agenesis of the gallbladder or cholecystectomy).&#xD;
&#xD;
          -  Participant has known or suspected biliary duct obstruction, or sphincter of Oddi&#xD;
             disease or dysfunction&#xD;
&#xD;
          -  Participant has a history of pancreatitis; structural diseases of the pancreas, known&#xD;
             or suspected pancreatic duct obstruction&#xD;
&#xD;
          -  Participant has a history of chronic or severe constipation, or sequelae from&#xD;
             constipation, or known or suspected mechanical GI obstruction or pseudo obstruction&#xD;
&#xD;
          -  Participant has renal impairment or an unstable hepatic, metabolic, or hematologic&#xD;
             condition.&#xD;
&#xD;
          -  Participant is a current regular alcohol drinker and/or binge drinker*, and/or has a&#xD;
             history of alcoholism, alcohol abuse (eg, binge-drinking*), or alcohol addiction,&#xD;
             and/or intends to consume alcohol during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kindred Medical Institute, LLC /ID# 227595</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Research Center, Inc. /ID# 227597</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 227600</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children /ID# 227601</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michael W. Simon, MD, PSC /ID# 227598</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IPS Research Company /ID# 227594</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians, Inc. /ID# 227596</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute /ID# 227602</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome with Diarrhea IBSD IBS-D Irritable Bowel Syndrome Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eluxadoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

